- Home
- Reports Store
- Medical Devices
Cardiovascular Devices Market
Customise your request
Need this report to answer something it does not cover? Tell us the decision you are facing and we will scope the work — or point you to a study that already answers it.
info@cortexmeridian.com+971 56 483 5090Report Scope
| Report ID / SKU | CM-MD-0004 |
|---|---|
| Report Code | CM-MD-P1-1004 |
| Report Type | Market Analysis & Forecast |
| Base Year | 2025 |
| Historical Period | 2021–2025 |
| Forecast Period | 2026–2035 |
| Geographic Scope | Global |
| Global Coverage | Yes |
| Regions Covered | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Countries Covered | US; Canada; Mexico; UK; Germany; France; Italy; Spain; Netherlands; Switzerland; China; India; Japan; South Korea; Australia; Brazil; Argentina; Saudi Arabia; UAE; South Africa (20 countries) |
| Market Size Unit | USD Billion |
| Volume Unit | Devices / Procedures / Installed Base |
| Report Format | PPT / WORD / EXCEL / PDF |
| Page Count | 180-220 |
| Delivery Timeline | 48 hours |
| Sample Available | Yes |
| Author / Analyst | Cortex Meridian Medical Devices Analyst Team |
| Publish Date | October 2026 |
| Last Updated | 2026-10-06 |
Market Overview & Definition

The global Cardiovascular Devices market is estimated by Cortex Meridian Research at USD 57.6 billion in 2025 and is forecast to reach approximately USD 122.1 billion by 2035, translating into a CAGR of 7.8%. The unusually strong growth profile reflects a broad structural migration from open surgery and episodic care toward catheter-based intervention, implantable therapy and continuous monitoring. This expands the treatable patient pool because older and higher-risk patients who may not qualify for conventional surgery can increasingly be treated through less invasive approaches.
Structural heart, rhythm management and interventional cardiology are the most important value pools. Leadless pacing, transcatheter valve replacement and advanced coronary intervention command premium pricing because they reduce procedural burden or extend treatment to previously undertreated patient groups. At the same time, remote monitoring and AI-assisted diagnostics are creating additional digital revenue around implanted devices and chronic follow-up.
Competitive moves are directly influencing market structure. Abbott’s AVEIR franchise is helping to accelerate leadless pacing, while Edwards Lifesciences continues to expand beyond core TAVR through structural-heart acquisitions and pipeline development. The blocked JenaValve transaction is strategically relevant because it preserves an independent competitor in TAVR for aortic regurgitation, reducing concentration in an emerging indication. The market’s growth is therefore being driven by both procedure expansion and technology mix shift toward higher-value therapies.
Report Description
The Cardiovascular Devices Market covers revenue generated from the defined medical-device products, related consumables and software/services where directly attached to the device workflow. The report excludes unrelated pharmaceuticals and stand-alone healthcare services. The scope is designed for manufacturers, suppliers, distributors, hospitals, diagnostic providers, investors and strategy teams evaluating demand, technology shifts, pricing and competitive opportunity.
Overall Market Dynamics
Drivers
High CVD burden, aging populations, minimally invasive procedures, structural-heart adoption, remote monitoring and device innovation.
Restraints / Risks
Stringent approvals, reimbursement constraints, recall risk, long sales cycles for capital systems and pricing pressure.
Opportunities
TAVR/structural heart, PFA/electrophysiology, leadless CRM, AI-enabled monitoring, ambulatory procedures and APAC expansion.
Strategic themes
AI/connectivity, workflow efficiency, reimbursement, regulatory approvals, recurring consumables/service revenue, and regional access expansion.
Segmentation & Scope

By product: diagnostic/monitoring devices, cardiac rhythm management, interventional cardiology, structural heart, peripheral vascular, cardiac surgery; by procedure; by end user: hospitals, ASCs, specialty clinics; by geography.
Regional & Country Outlook

COUNTRY CHAPTER COVERAGE 1. US: market size; procedure volumes; TAVR/PCI/CRM penetration; FDA pipeline; reimbursement; Abbott/Medtronic/Edwards/Boston Scientific competition. 2. Canada: procedure volumes; structural heart; CRM; provincial reimbursement; hospital procurement. 3. UK: NHS cardiology capacity; PCI/TAVR; rhythm management; waiting lists; procurement; reimbursement. 4. Germany: high procedural density; TAVR; EP/CRM; reimbursement; hospital adoption; supplier competition. 5. France: structural heart; interventional cardiology; reimbursement; hospital volumes; device adoption. 6. Italy: PCI/TAVR/CRM demand; regional hospital capacity; reimbursement; procurement. 7. Spain: cardiac procedure volumes; TAVR/PCI; public hospital procurement; reimbursement. 8. Netherlands: advanced structural-heart and EP adoption; high-value devices; digital monitoring. 9. Switzerland: premium cardiovascular technologies; private/public hospital mix; structural heart; CRM. 10. China: PCI volume; TAVR growth; local device companies; volume-based procurement; pricing; regulatory approvals. 11. India: high CAD burden; PCI; TAVR growth; price caps; domestic manufacturing; hospital expansion. 12. Japan: aging population; TAVR/CRM; reimbursement; domestic and multinational competition. 13. South Korea: advanced cardiac intervention; TAVR/EP; reimbursement; hospital technology adoption. 14. Australia: TAVR/PCI/CRM; reimbursement; cardiac centers; remote monitoring. 15. Brazil: PCI and rhythm management; public/private access; import pricing; hospital concentration. 16. Argentina: cardiology procedures; import dependency; pricing; reimbursement; private hospitals. 17. Saudi Arabia: cardiac center investment; PCI/TAVR; Vision 2030; tenders; localization. 18. UAE: premium cardiology services; structural heart; private hospitals; technology adoption. 19. South Africa: public/private cardiology split; PCI/CRM access; reimbursement; distribution.
Competitive Landscape & Companies Covered
Medtronic; Abbott; Boston Scientific; Edwards Lifesciences; GE HealthCare; Siemens Healthineers; Philips; BIOTRONIK; Terumo; B. Braun; LivaNova; W. L. Gore
Pricing & Ecosystem
Pricing, Cost & Revenue Intelligence
Pricing intelligence benchmarks capital-system ASPs, disposable/consumable pricing, procedure-linked device pricing, service contracts, software subscriptions and regional tender dynamics where applicable. The model distinguishes capital equipment from recurring revenue and evaluates discounting, bundling, distributor margins, reimbursement sensitivity and premium technology price realization.
Value Chain & Ecosystem Analysis
The ecosystem maps component and sensor suppliers, materials vendors, device OEMs, software/AI partners, contract manufacturers, sterilization and packaging providers, distributors, hospitals/diagnostic laboratories/ASCs, clinicians, payers and regulators. The analysis identifies control points in the value chain, recurring-revenue pools, channel dependencies and partnership opportunities.
Opportunity & White-Space Analysis
A weighted opportunity model scores product segments, technologies, countries, end users and accounts using growth, market size, clinical adoption, reimbursement, competitive intensity, regulatory accessibility and margin potential. Priority white spaces include TAVR/structural heart, PFA/electrophysiology, leadless CRM, AI-enabled monitoring, ambulatory procedures and APAC expansion.
Executive Summary
Cortex Meridian Research estimates the Cardiovascular Devices market at USD 57.6 billion in 2025, reaching approximately USD 122.1 billion by 2035 at a CAGR of 7.8%. The strongest growth is coming from technologies that expand treatment eligibility and reduce procedural invasiveness, particularly structural-heart intervention, leadless pacing and advanced catheter-based therapies.
Abbott’s AVEIR platform is materially strengthening the leadless-pacing segment, while Edwards Lifesciences’ acquisition activity shows how aggressively leading vendors are positioning for the next wave of structural-heart growth. The decision to block Edwards’ proposed JenaValve acquisition preserves competitive pressure in TAVR for aortic regurgitation and may encourage further innovation. As device therapy becomes more connected and less invasive, the market is shifting toward higher-value procedures with stronger recurring follow-up economics.
Key Takeaways
- 2025 Cortex normalized estimate: USD 57.6 billion
- 2035 normalized outlook: USD 122.1 billion
- Normalized 2025–2035 CAGR: 7.8%
- Key growth drivers: High CVD burden, aging populations, minimally invasive procedures, structural-heart adoption, remote monitoring and device innovation.
- Priority opportunity areas: TAVR/structural heart, PFA/electrophysiology, leadless CRM, AI-enabled monitoring, ambulatory procedures and APAC expansion.
- Primary competitive set: Medtronic; Abbott; Boston Scientific; Edwards Lifesciences; GE HealthCare; Siemens Healthineers; Philips; BIOTRONIK; Terumo; B. Braun; LivaNova; W. L. Gore
Table of Contents
List of Tables
- Global market value, 2021–2035
- Market by product/device type
- Market by technology
- Market by application/procedure
- Market by end user
- Market by region
- Country market sizing
- Installed base/procedure/test indicators
- ASP/pricing benchmark
- Company/product benchmark
- Opportunity attractiveness scoring
List of Figures
- Market size and CAGR outlook
- Segment attractiveness matrix
- Technology adoption curve
- Regional opportunity heat map
- Competitive positioning matrix
- Value-chain ecosystem map
- Pricing/revenue model
- Opportunity prioritization matrix
Research Methodology
Methodology
Cortex Meridian Research applies a triangulated market-sizing framework combining company disclosures, regulatory databases, procedure/test volumes, installed-base indicators, shipment and utilization data, hospital and laboratory purchasing patterns, reimbursement signals, product approvals, and primary research. Public market benchmarks are used only as external calibration points; Cortex values are normalized to the defined scope and forecast period. Forecasts consider technology adoption, procedure/test growth, replacement cycles, pricing, reimbursement, regulatory changes, and regional healthcare investment.
Data Sources & Validation
Company annual reports and investor materials; FDA, EMA and other regulatory databases; WHO and national health agencies; peer-reviewed clinical literature; procurement and reimbursement sources; hospital/laboratory statistics; trade and shipment indicators; company product portfolios; primary interviews; and public market benchmarks used for calibration.
FAQ — Buyer Questions
Q: What is the 2025 global Cardiovascular Devices market size? A: Cortex Meridian Research estimates it at approximately USD 57.6 billion.
Q: What is the 2035 market outlook? A: The normalized outlook is approximately USD 122.1 billion, based on a 7.8% CAGR assumption.
Q: What are the major growth drivers? A: High CVD burden, aging populations, minimally invasive procedures, structural-heart adoption, remote monitoring and device innovation.
Q: Which opportunities should suppliers prioritize? A: TAVR/structural heart, PFA/electrophysiology, leadless CRM, AI-enabled monitoring, ambulatory procedures and APAC expansion.
Customization Options
Customization can include country-level sizing, procedure/test volumes, installed base, ASP benchmarking, hospital/lab account mapping, competitor benchmarking, product pipeline analysis, regulatory and reimbursement tracking, KOL mapping, distributor/channel assessment, and opportunity prioritization.
Need something this report does not cover?
Describe the decision you are facing. If a published study already answers it we will point you there; if not, we will scope the work and come back with timeline and cost.
CM-MD-0004 · CM-MD-P1-1004 · 180-220 pages · Published October 2026 · Cortex Meridian Medical Devices Analyst Team
